Search

Your search keyword '"Ganzinelli M"' showing total 44 results
Start Over Author "Ganzinelli M" Search Limiters Peer Reviewed
44 results on '"Ganzinelli M"'

1. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

Author

Proto, C., Ganzinelli, M., Manglaviti, S., Imbimbo, M., Galli, G., Marabese, M., Zollo, F., Alvisi, M.F., Perrino, M., Cordua, N., Borea, F., de Vincenzo, F., Chella, A., Cappelli, S., Pardini, E., Ballatore, Z., Lucarelli, A., Ambrosini, E., Giuliano, M., Pietroluongo, E., Mulargiu, C., Fabbri, A., Prelaj, A., Occhipinti, M., Brambilla, M., Mazzeo, L., Beninato, T., Vigorito, R., Ruggirello, M., Greco, F.G., Calareso, G., Miliziano, D., Rulli, E., De Simone, I., Torri, V., de Braud, F.G.M., Pasello, G., De Placido, P., Berardi, R., Petrini, I., Zucali, P., Garassino, M.C., and Lo Russo, G.

Published
2024
Full Text
View/download PDF

2. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

Author

Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S.E., Mazzeo, L., Provenzano, L., Kosta, S., Favali, M., Spagnoletti, A., Castelo-Branco, L., Dolezal, J., Pearson, A.T., Lo Russo, G., Proto, C., Ganzinelli, M., Giani, C., Ambrosini, E., Turajlic, S., Au, L., Koopman, M., Delaloge, S., Kather, J.N., de Braud, F., Garassino, M.C., Pentheroudakis, G., Spencer, C., and Pedrocchi, A.L.G.

Published
2024
Full Text
View/download PDF

3. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

Author

Lo Russo, G., Sgambelluri, F., Prelaj, A., Galli, F., Manglaviti, S., Bottiglieri, A., Di Mauro, R.M., Ferrara, R., Galli, G., Signorelli, D., De Toma, A., Occhipinti, M., Brambilla, M., Rulli, E., Triulzi, T., Torelli, T., Agnelli, L., Brich, S., Martinetti, A., Dumitrascu, A.D., Torri, V., Pruneri, G., Fabbri, A., de Braud, F., Anichini, A., Proto, C., Ganzinelli, M., Mortarini, R., and Garassino, M.C.

Published
2022
Full Text
View/download PDF

7. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

Author

Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Nerini, I. Fuso, Damia, G., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., Chiorino, G., Giandomenico, Di S., Rocchi, M., Capozzi, O., Margison, G. P., Watson, A. J., Caccuri, A. M., Pastore, A., Fossati, A., Mantovani, R., Grosso, F., Tercero, J. C., Erba, E., and DʼIncalci, M.

Published
2012
Full Text
View/download PDF

8. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Author

Proto, C., Ferrara, R., Signorelli, D., Lo Russo, G., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L.M., De Simone, I., Colombo, M.P., Sica, A., Torri, V., and Garassino, M.C.

Abstract

Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition has shown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first line tyrosine kinase inhibitors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

14. Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations

Author

Ganzinelli, M., Mariani, P., Cattaneo, D., Fossati, R., Fruscio, R., Corso, S., Ricci, F., Broggini, M., and Damia, G.

Subjects
*ANALYSIS of variance, *CHI-squared test, *CONFIDENCE intervals, *DNA, *GENE expression, *MULTIVARIATE analysis, *OVARIAN tumors, *PROBABILITY theory, *SURVIVAL analysis (Biometry), *TUMOR classification, *PROPORTIONAL hazards models, *RETROSPECTIVE studies
Abstract

Abstract: The purpose of this study was to investigate retrospectively the mRNA expression of genes involved in different DNA repair pathways implicated in processing platinum-induced damage in 171 chemotherapy-naïve ovarian tumours and correlate the expression of the different genes with clinical parameters. The expression of genes involved in DNA repair pathways (PARP1, ERCC1, XPA, XPF, XPG, BRCA1, FANCA, FANCC, FANCD2, FANCF and PolEta), and in DNA damage transduction (Chk1 and Claspin) was measured by RT-PCR in 13 stage I borderline and 77 stage I and 88 III ovarian carcinomas. ERCC1, XPA, XPF and XPG genes were significantly less expressed in stage III than in stage I carcinoma; BRCA1, FANCA, FANCC, FANCD2 gene expressions were low in borderline tumours, higher in stage I carcinomas and lower in stage III samples. High levels of ERCC1, XPA, FANCC, XPG and PolEta correlated with an increase in Overall Survival (OS) and Progression Free Survival (PFS), whilst high BRCA1 levels were associated with PFS on univariate analysis. With multivariate analyses no genes retained an association when adjusted by stage, grade and residual tumour. A tendency towards a better PFS was observed in patients with the highest level of ERCC1 and BRCA1 after platinum-based therapy than those given both platinum and taxol. The expression of DNA repair genes differed in borderline stage I, stage I and stage III ovarian carcinomas. The role of DNA repair genes in predicting the response in ovarian cancer patients seems far from being established. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

18. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs).

Author

Manglaviti, S., Galli, G., Bini, M., Labianca, A., Zecca, E., Brambilla, M., Occhipinti, M., Proto, C., Prelaj, A., Signorelli, D., De Toma, A., Viscardi, G., Beninato, T., Zattarin, E., Ganzinelli, M., de Braud, F.G.M., Garassino, M.C., Lo Russo, G., and Ferrara, R.

Published
2021
Full Text
View/download PDF

28. Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells

Author

Geroni Cristina, Caiola Elisa, Ganzinelli Monica, Marabese Mirko, Sabatino Maria, and Broggini Massimo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Drug resistance is one of the major obstacles limiting the activity of anticancer agents. Activation of DNA repair mechanism often accounts for increase resistance to cancer chemotherapy. Results We present evidence that nemorubicin, a doxorubicin derivative currently in clinical evaluation, acts through a mechanism of action different from classical anthracyclines, requiring an intact nucleotide excision repair (NER) system to exert its activity. Cells made resistant to nemorubicin show increased sensitivity to UV damage. We have analysed the mechanism of resistance and discovered a previously unknown mechanism resulting from methylation-dependent silencing of the XPG gene. Restoration of NER activity through XPG gene transfer or treatment with demethylating agents restored sensitivity to nemorubicin. Furthermore, we found that a significant proportion of ovarian tumors present methylation of the XPG promoter. Conclusions Methylation of a NER gene, as described here, is a completely new mechanism of drug resistance and this is the first evidence that XPG gene expression can be influenced by an epigenetic mechanism. The reported methylation of XPG gene could be an important determinant of the response to platinum based therapy. In addition, the mechanism of resistance reported opens up the possibility of reverting the resistant phenotype using combinations with demethylating agents, molecules already employed in the clinical setting.

Published
2010
Full Text
View/download PDF

30. 178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients.

Author

Provenzano, L., Favali, M., Mazzeo, L., Spagnoletti, A., Giani, C., Calareso, G., Ruggirello, M., Greco, F.G., Vigorito, R., Occhipinti, M., Brambilla, M., Manglaviti, S., Proto, C., Lo Russo, G., Trovò, F., De Braud, F.G.M., Ganzinelli, M., Pedrocchi, A., Miskovic, V., and Prelaj, A.

Subjects
*MACHINE learning, *NON-small-cell lung carcinoma, *IMMUNE checkpoint inhibitors, *TREATMENT effectiveness, *RADIOMICS, *IPILIMUMAB
Published
2023
Full Text
View/download PDF

31. 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib.

Author

Brambilla, M., Lorenzini, D., Occhipinti, M., Manglaviti, S., Beninato, T., Mazzeo, L., Agnelli, L., Leporati, R., Zanella, C., Leone, A.G., Fotia, G., Prelaj, A., Lo Russo, G., Grande, I., Tamborini, E., Perrone, F., Ganzinelli, M., Pruneri, G., De Braud, F.G.M., and Proto, C.

Subjects
*NON-small-cell lung carcinoma, *GENE frequency, *OSIMERTINIB, *EPIDERMAL growth factor receptors
Published
2023
Full Text
View/download PDF

32. 1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC.

Author

Bottiglieri, A., Provenzano, L., Spagnoletti, A., Mazzeo, L., Ganzinelli, M., Lo Russo, G., Ferrara, R., Proto, C., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Beninato, T., Garassino, M.C., Filosa, J., Di Guida, G., De Braud, F.G.M., Viscardi, G., Della Corte, C.M., and Prelaj, A.

Subjects
*RAS oncogenes, *NON-small-cell lung carcinoma, *BIOPSY, *LIQUIDS
Published
2022
Full Text
View/download PDF

33. 1079P Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations.

Author

Beninato, T., Brambilla, M., Pircher, C.C., Mazzeo, L., Rametta, A., Manglaviti, S., De Toma, A., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Lo Russo, G., Ganzinelli, M., Di Mauro, R., Di Nucci, A., Garassino, M.C., Marchetti, P., De Braud, F.G.M., and Occhipinti, M.

Subjects
*NON-small-cell lung carcinoma, *IMMUNE checkpoint inhibitors, *IPILIMUMAB
Published
2022
Full Text
View/download PDF

34. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations

Author

Ferrara, R., Lo Russo, G., Ciniselli, C.M., Di Gregorio, S., Calareso, G., Bassani, B., Proto, C., Prelaj, A., De Toma, A., Occhipinti, M., Brambilla, M., Manglaviti, S., Mazzeo, L., Beninato, T., Ganzinelli, M., De Braud, F.G.M., Garassino, M.C., Colombo, M.P., Verderio, P., and Sangaletti, S.

Subjects
*NON-small-cell lung carcinoma, *PROGRAMMED cell death 1 receptors, *PROGRAMMED death-ligand 1, *NEUTROPHILS, *CANCER chemotherapy
Published
2022
Full Text
View/download PDF

35. 1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients.

Author

Prelaj, A., Bottiglieri, A., Provenzano, L., Spagnoletti, A., Mazzeo, L., Miskovic, V., Ganzinelli, M., Lo Russo, G., Ferrara, R., Proto, C., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Beninato, T., Rametta, A., Garassino, M.C., De Braud, F.G.M., Trovò, F., and Pedrocchi, A.

Subjects
*NON-small-cell lung carcinoma, *TRUST, *ARTIFICIAL intelligence, *CANCER patients, *GENOMICS
Published
2022
Full Text
View/download PDF

36. 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience.

Author

Lobefaro, R., Viscardi, G., Di Liello, R., Massa, G., Iacovino, M.L., Sparano, F., Della Corte, C.M., Ferrara, R., Signorelli, D., Proto, C., Prelaj, A., Galli, G., De Toma, A., Brambilla, M., Ganzinelli, M., Trevisan, B., De Braud, F.G.M., Morgillo, F., Garassino, M.C., and Lo Russo, G.

Subjects
*IMMUNE checkpoint inhibitors, *NON-small-cell lung carcinoma, *BIOMARKERS
Published
2020
Full Text
View/download PDF

37. 1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis.

Author

Brambilla, M., Nichetti, F., Loberfaro, R., Galli, G., De Toma, A., Viscardi, G., Prelaj, A., Ferrara, R., Proto, C., Signorelli, D., Bottiglieri, A., Massa, G., Trevisan, B., Ganzinelli, M., Zilembo, N., de Braud, F., Garassino, M.C., and Lo Russo, G.

Subjects
*IMMUNOTHERAPY, *PROGRAMMED death-ligand 1, *CANCER chemotherapy, *NON-small-cell lung carcinoma
Published
2020
Full Text
View/download PDF

38. 112P - DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.

Author

Prelaj, A., Proto, C., Russo, G Lo, Signorelli, D., Ferrara, R., Galli, G., De Toma, A., Randon, G., Pagani, F., Travisan, B., Ganzinelli, M., Zilembo, N., De Braud, F.G.M., Mensah, M., Torri, V., Garassino, M.C., Sozzi, G., and Boeri, M.

Subjects
*OVERALL survival, *SURVIVAL rate, *IMMUNOTHERAPY, *NON-small-cell lung carcinoma, *PROGNOSIS, *OVARIAN epithelial cancer
Abstract

The DiMaio (D), EPSILoN (E) and plasma microRNA signature classifier (MSC), are 3 diverse clinico-biochemical and molecular scores able to independently predict prognosis in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immunotherapy (IO). By assessing the ability of each test a combined score (SC) called DEMo was developed. The study aims to prospectively evaluate the prognostic value of DEMo in aNSCLC pts treated with IO. We included in the analyses 166 aNSCLC pts treated in 1L (n = 47) and further-lines (n = 119) with IO at Istituto Nazionale Tumori of Milan. For all pts we obtained complete necessary data for both clinical SC: D (sex, histology, ECOG-PS stage, uses of platinum-based therapy at 1L and response to 1L) and E (ECOG-PS, Smoke, Liver, LDH, NL-ratio). MSC was prospectively evaluated in plasma samples collected at baseline IO and the risk level was assessed. Endpoints were median overall survival (mOS), progression-free survival (mPFS) and overall response rate (ORR). Kaplan-Meier and Cox model were used to generate survival curves and multivariate analyses, respectively. In multivariate analysis adjusted for age, sex, smoke and ECOG-PS each score remain independently significant for both PFS (D: HR = 1.99, CI95% 1.21–3.03, p = 0.007; E: HR = 1.87 CI95% 1.12 – 3.10, p = 0.016; MSC: HR = 1.56, CI95% 1.03–2.37, p = 0.0370) and OS (D: HR = 3.12, CI95% 1.80–5.41, p = 0.0001; E: HR = 2.21, CI95% 1.28–3.79, p = 0.0041; MSC: HR = 2.03, CI95% 1.30–3.17, p = 0.0019). DEMo separated patients in 4-risk groups (gr) based on the presence of 3–2–1–0 poor prognostic SC. Strata had 0%–7%–20%–46% 18 months (mo) PFS (p < 0.0001) and 0%–23%–44%–78% 18 mo OS (p < 0.0001). We further combined DEMo gr 3/2 and 0/1 for multivariate analysis: mPFS and mOS for gr 3/2 vs 0/1 were 2.1 vs 6.4 mo (HR = 2.06, CI95% 1.26–3.36, p = 0.0038) and 4.1 vs 20.3 mo (HR 3.17, CI95% 1.91–5.24, p < 0.0001). The ORR was 2.9 (CI95% 1.4–6.0) fold higher for gr 0/1 compare to 3/2 (p = 0.0034). We created a composite clinic-molecular combined biomarker classifier able to better predict prognosis compared to each single SC and to select patients who less likely benefit from IO. DEMo could be a useful tool to guide choices in aNSCLC. The authors. Fondazione IRCCS Istituto Nazionale Tumori of Milan, Italy. Has not received any funding. All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

39. 188TiP Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial.

Author

Galli, G, Signorelli, D, Vernieri, C, Ganzinelli, M, Moro, M, Fabbri, A, Tamborini, E, Marabese, M, Caiola, E, Broggini, M, Hollander, L, Gallucci, R, Gavazzi, C, Rizzo, A M, Corsetto, P, Pruneri, G, Braud, F de, Sozzi, G, Torri, V, and Garassino, M C

Subjects
*COMBINATION drug therapy, *FASTING, *LUNGS, *METFORMIN, *ADENOCARCINOMA
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results